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Abstract: Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth 
factor (VEGF). It is a novel chemotherapeutic agent currently approved as part of combination 
chemotherapy for metastatic colorectal cancer, non-small cell lung cancer, and breast cancer 
(Hurwitz et al 2004; Sandler et al 2006; Traina et al 2007). Arterial thrombosis, including cerebral 
infarction, transient ischemic attacks, myocardial infarction, and angina are common, occurring 
in 4.4% of patients whose regimen includes bevacizumab (versus 1.9% on regimen without 
bevacizumab) (Genetech, Inc. 2008). This series will review two cases of patients exposed to 
bevacizumab who subsequently developed ST elevations on electrocardiogram (ECG) and 
elevated cardiac biomarkers. Both patients underwent cardiac catheterization, which demon-
strated apical ballooning and akinesis in a distribution discordant with the observed (noncritical) 
atherosclerotic lesions. Both patients had recovery of left ventricular function within 30 days. 
The clinical presentation, including ECGs and ﬁ  ndings on catheterization as well as the rapid 
recovery of ventricular function, is consistent with the diagnosis of takotsubo cardiomyopathy. 
Takotsubo cardiomyopathy was ﬁ  rst described in 1991, but the pathophysiology and exact 
mechanism of injury remain largely unknown. These two cases are notable for their occurrence 
in men and the association with treatment of metastatic cancer including bevacizumab.
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Introduction
Takotsubo cardiomyopathy was originally described in 1991 by Dote and colleagues. 
The appearance of the apical ballooning on ventriculography (characterized by a round 
base and narrow neck) resembles a vessel used in Japan as an octopus trap. The vessel is 
called takot subo, thus, the syndrome named (Dote et al 1991). The takotsubo syndrome 
has garnered much attention with a series of case reports and reviews in the recent 
literature. Initially thought to be limited to Japan and geographically and/or racially 
selective, case reports in Caucasian populations throughout the United States and 
Europe have increased. It remains unclear whether this effect is due to a true increase 
in the incidence or if it is due to more widespread recognition of the syndrome.
Takotsubo syndrome is characterized by the abrupt onset of angina-like chest pain, 
ST elevations and/or T wave inversions, subsequent elevation of cardiac biomarkers, 
and a marked decrease in left ventricular systolic function. It occurs most commonly 
in women, aged 62 to 75. Patients generally present with chest pain, but may also 
complain of dyspnea or rarely, syncope (Bybee et al 2004). Imaging of the ventricular 
function reveals a hyperdynamic basal segment and apical akinesis of the left ventricle, 
whereby takotsubo mimics acute myocardial infarction (Dote et al 1991; Bybee et al 
2004).There remain, however, important differences between the two diagnoses. 
For example, in takotsubo cardiomyopathy, peak troponin values are often observed 
on initial presentation as opposed to the later peak as seen in myocardial infarction. Therapeutics and Clinical Risk Management 2008:4(6) 1368
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Furthermore, if any coronary artery disease is discovered 
on angiogram, it is incongruent with the akinesis visual-
ized. Finally, in takotsubo cardiomyopathy, resolution of the 
impaired left ventricular systolic function occurs in 7 to 30 
days following presentation (Bybee et al 2004).
The pathogenesis of takotsubo cardiomyopathy is 
incompletely understood. Transient myocardial arterial 
thrombosis, with subsequent dislodgement of clot or plaque 
seems unlikely because of the absence of a plausible blockage 
of coronary arterial territory producing ischemia congruent 
with the area in which the akinesis is seen. Lymphocytic 
myocarditis is characterized by a reversible deﬁ  cit of left 
ventricular output due to hypokinesis in areas extending 
beyond a single coronary artery. The hypokinesis seen in 
myocarditis, however, is global and does not have the char-
acteristic apical ballooning seen with takotsubo. Coronary 
vasospasm without thrombosis is also a consideration; 
however, past studies have failed to determine clearly 
if vascular spasm is the direct mechanism of injury or if 
the vascular spasm is simply a secondary phenomenon in 
takotsubo cardiomyopathy (Bybee et al 2004). The most 
commonly accepted theory is that stress induced catechol-
amine release causes myocardial damage by microvascular 
spasm or by direct cardiotoxicity. Microvascular ischemia 
might account for the lack of a single coronary artery terri-
tory producing ischemia in the apical area of akinesis (Dote 
et al 1991; Bybee et al 2004). Adrenergic receptor density 
appears to be heterogeneous throughout the left ventricle, 
which might explain the regional variation in myocardial 
damage that is observed during the high catecholamine state. 
Parallels have been drawn to the myocardial stunning seen 
with subarachnoid hemorrhage and high levels of catechol-
amines found in pheochromocytoma. Genetic variations 
in catecholamine receptor location could place susceptible 
individuals at increased risk for this syndrome (Van De 
Walle et al 2006).
Although takotsubo syndrome is normally found in 
women, both patients in these cases were men (Dote et al 
1991; Bybee et al 2004). Both patients received bevacizumab 
as chemotherapy for metastatic cancer. Bevacizumab is 
a vascular endothelial growth factor (VEGF) inhibitor. 
VEGF inhibition is a novel target for chemotherapy, and the 
potential utility of this class of drugs is quite large. While 
the role of VEGF in embryonic development and neoplastic 
processes is widely accepted, it is not clear what role this 
molecule might have in the adult vascular system. There is 
some suggestion that VEGF may perform arterioprotective 
functions (Zachary et al 2006). In an experiment designed to 
elucidate the molecular biology of cardiotoxicity secondary 
to chemotherapy, high levels of inﬂ  ammatory cytokines 
and chemoattractant proteins were isolated in the plasma 
and myocardial tissue of mice that were exposed to beva-
cizumab. Researchers have proposed that the expression of 
these inﬂ  ammatory cytokines and chemoattractant proteins 
in plasma during anti-cancer therapy could be indicative 
of cardiotoxicity (Drimal et al 2006). In an animal model 
of heart failure and pressure overload (with transaortic 
constriction), mice that were genetically engineered to block 
signaling of VEGF demonstrated a reduction in cardiac 
hypertrophy with increased left ventricle dilatation and a loss 
in contractile function. These ﬁ  ndings suggest that inhibition 
of VEGF is associated with the transition from compensatory 
hypertrophy to overt failure (Izumiya et al 2006).
VEGF inhibition has also been associated with arterial 
thrombotic events. A recent meta-analysis, which included 
ﬁ  ve randomized controlled trials, found that the risk of 
arterial thrombosis was higher in cancer patients receiving 
bevacizumab as part of their regimen, than in those patients 
whose regimen did not include bevacizumab (Scappaticci et al 
2007). These ﬁ  ndings are consistent with the statistics from 
prescribing information for bevacizumab. Arterial thrombotic 
events, such as myocardial infarction and angina, occurred 
in 4.4% of patients whose regimen included bevacizumab as 
opposed to 1.9% of patients on a regimen without bevaci-
zumab (Genetech, Inc. 2008). Given the similarities between 
myocardial infarction and takotsubo cardiomyopathy, it 
is conceivable that some of the arterial thrombotic events 
recorded as myocardial infarction might actually have been 
unrecognized incidents of takotsubo cardiomyopathy.
There are currently 130 bevacizumab clinical trials for 25 
different types of cancer. If there is direct cardiotoxicity or other 
deleterious vascular effects inherent in this class of drugs, the 
implications and number of patients affected are substantial.
Cases
In the first case, a 76-year-old man with colon cancer 
presented to the emergency room with fever and hypotension 
2 days after initiating chemotherapy with bevacizumab. The 
ECG (Figure 1) demonstrated diffuse anterior and infe-
rior ST-segment elevations in the setting of elevated 
troponin (11.4 ng/mL). Emergent cardiac catheterization 
revealed noncritical left main coronary artery disease and 
atherosclerosis in the right coronary artery (Figure 2a, 2b).
Echocardiography showed decreased systolic function with 
apical akinesis and a hyperdynamic basal segment of the left 
ventricle, which was discordant with the ﬁ  ndings at cardiac Therapeutics and Clinical Risk Management 2008:4(6) 1369
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catheterization. The patient’s fever and hypotension subsided 
without intervention and no source of infection was identiﬁ  ed. 
Approximately 3 weeks later, during a separate admission 
for lower gastrointestinal bleeding, minimally invasive 
hemodynamic and cardiac monitoring revealed normal cardiac 
output, consistent with recovery of left ventricular function.
In the second case, a 61-year-old man with metastatic 
non-small cell lung cancer presented to the emergency room 
with hemoptysis. The patient was tachycardic, with a heart 
rate of 100, but normotensive with pulse oximetry of 98%. 
Three weeks prior to admission, the patient had received 
the second dose of chemotherapy including bevacizumab. 
The ECG (Figure 3) demonstrated new Q-waves in the 
inferior and precordial leads, as well as diffuse ST elevation 
suggestive of acute ischemia. Creatine-kinase (CK) and 
CK-MB (CK-muscle and brain) were normal, but troponin 
was elevated (2.5 ng/mL). On cardiac catheterization, the 
patient had severely depressed left ventricular function with 
no evidence of coronary arterial stenosis (Figure 2c, 2d). 
The hemoptysis resolved and no further hemodynamic 
compromise was observed. An ECG on the third day of 
hospitalization showed resolution of the ST elevations, but 
the Q-waves persisted. An echocardiogram performed on day 
15 of his hospitalization was notable for signiﬁ  cant recovery 
of ventricular function.
Discussion
The differential diagnosis of acute myocardial infarction 
in the absence of critical coronary artery disease is broad. 
It includes cocaine intoxication, coronary vasospasm, 
prolonged hypotension, sepsis, micro-embolic occlusion, 
CNS trauma, vasculitis, coronary artery dissection, and 
takotsubo cardiomyopathy. After appropriate diagnostic 
evaluation, and in light of the fact that both patients met all 
four of the proposed Mayo Criteria for the clinical diagnosis 
of transient left ventricular apical ballooning syndrome 
(takotsubo cardiomyopathy), the consensus was that both 
patients had clinical presentations most consistent with 
takotsubo cardiomyopathy (Bybee et al 2004).
The cases are somewhat atypical in that both occurred in 
men and neither patient complained of chest pain. However, 
both patients had prominent, diffuse ST segment elevations 
on ECG, the most common ECG finding in takotsubo 
cardiomyopathy. New Q-waves have been observed in 
up to 31% of patients, and in some instances, the Q-waves 
have been a transient phenomenon (Bybee et al 2004). 
As illustrated in Figure 3, the second patient did have 
Q-waves on presentation. In this case, the Q-waves persisted 
despite recovery of ventricular function. Figures 4a and 4b 
Figure 1 The ECG for case one demonstrated prominent ST elevations in the 
anterior and inferior leads.
Figure 2 In case one, noncritical, distal lesions of the right coronary artery (RCA) 
(a) and noncritical atherosclerotic lesions of the left main coronary artery (b) did 
not correspond with the wall motion abnormality observed on ventriculography. In 
case two, there was no evidence of coronary arterial stenosis of either the RCA (c) 
or the left anterior descending artery (d).
Figure 3 In the second case, the ECG was notable for new Q-waves in inferior and 
precordial leads as well as ST elevation suggestive of acute ischemia or injury in the 
anterior-septal leads.Therapeutics and Clinical Risk Management 2008:4(6) 1370
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show clearly that both patients had signiﬁ  cant left ventricular 
dysfunction. In Figure 4a, there appears to be some degree 
of asymmetry in the balloon effect. While takotsubo 
cardiomyopathy is classically described as apical ballooning, 
cases of midventricular ballooning have been reported. 
Although the exact mechanism is unclear, it is believed that 
the pathophysiology underlying transient midventricular 
ballooning is the same as that of takotsubo cardiomyopa-
thy (Hurst et al 2006). In the second case, Figure 4b, the 
ventricular ballooning is more classical in distribution, 
more closely resembling the octopus trap. In both cases, the 
affected area is not related to a single coronary artery distribu-
tion, which supports an etiology other than coronary artery 
disease. This is a hallmark feature of takotsubo cardiomyopa-
thy. Another prominent feature is the recovery of ventricular 
function within weeks. Both patients demonstrated recovery 
of myocardial function within 30 days.
These cases are notable for their occurrence in men 
and the association with treatment of metastatic cancer 
including bevacizumab. The cases described, animal mod-
els and data from clinical trials implicate bevacizumab as 
a potential cause of takotsubo cardiomyopathy in some 
patients. Although the exact mechanism of the suspected 
cardiotoxicity remains unknown, the discovery of this side 
effect may provide insights on the pathogenesis of takotsubo 
cardiomyopathy.
Conclusion
Bevacizumab is a novel chemotherapeutic agent, which 
inhibits VEGF – a promising target for anti-neoplastic agents. 
We have presented two cases of takotsubo cardiomyopathy, 
which developed after exposure to bevacizumab. The 
exact nature of the relationship between exposure to 
bevacizumab, the subsequent VEGF inhibition, and takotsubo 
cardiomyopathy remains to be seen. Further studies regarding 
the potential tonic arterioprotective effects of VEGF and the 
potential role of VEGF inhibition in the pathophysiology of 
takotsubo cardiomyopathy are warranted.
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Figure 4 (a) This image is a left ventriculogram obtained during systole in the ﬁ  rst 
patient. Hypercontractility of the basal segment and akinesis of the apical segment 
create the apical ballooning effect. (b) The ventriculogram obtained in the second case 
also demonstrates apical ballooning.